Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Acute myelogenous leukemia (AML)

AML1-ETO oncogenic fusion protein; cyclooxygenase-2 (COX-2)

In vitro and mouse studies suggest COX-2 inhibitors could help treat AML1-ETO+ AML. In normal mouse bone marrow cells, AML1-ETO overexpression increased both levels of Cox-2 and the self-renewing capacity of hematopoietic stem cells compared with no overexpression. In xenograft and orthotopic mouse models for AML1-ETO+ AML, a COX-2 inhibitor decreased the number and size of tumors compared with vehicle. Planned work includes a Phase II trial of an undisclosed NSAID to prevent relapse in AML.
At least five companies have COX-2 inhibitors approved to treat pain, rheumatoid arthritis (RA), osteoarthritis and other indications.

SciBX 6(20); doi:10.1038/scibx.2013.482
Published online May 23, 2013

Unpatented; available for partnering

Zhang, Y. et al. Blood; published online May 3, 2013;
doi:10.1182/blood-2012-08-447763
Contact: Jing-Ruey Joanna Yeh, Harvard Medical School, Boston, Mass.
e-mail:
jyeh1@partners.org